GH Research/$GHRS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About GH Research
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.
Ticker
$GHRS
Sector
Primary listing
Employees
50
Headquarters
Dublin, Ireland
Website
GH Research Metrics
BasicAdvanced
$781M
-
-$0.73
0.97
-
Price and volume
Market cap
$781M
Beta
0.97
52-week high
$20.50
52-week low
$6.72
Average daily volume
277K
Financial strength
Current ratio
29.488
Quick ratio
29.253
Long term debt to equity
0.093
Total debt to equity
0.213
Interest coverage (TTM)
-74.42%
Profitability
EBITDA (TTM)
-52.92
Management effectiveness
Return on assets (TTM)
-12.73%
Return on equity (TTM)
-16.35%
Valuation
Price to book
2.58
Price to tangible book (TTM)
2.58
Price to free cash flow (TTM)
-17.469
Free cash flow yield (TTM)
-5.72%
Free cash flow per share (TTM)
-0.721
Growth
Earnings per share change (TTM)
8.92%
3-year earnings per share growth (CAGR)
49.73%
What the Analysts think about GH Research
Analyst ratings (Buy, Hold, Sell) for GH Research stock.
Bulls say / Bears say
GH001 achieved its Phase 2b primary endpoint in Q1 2025, showing a placebo-adjusted MADRS reduction of 15.5 points and a 57.5% remission rate at Day 8 in patients with treatment-resistant depression, highlighting strong clinical efficacy.
A six-month open-label extension confirmed a 73% remission rate with infrequent GH001 dosing and no required psychotherapy, demonstrating sustained, durable response.
As of June 30, 2025, GH Research held $308.7 million in cash, equivalents and marketable securities, providing ample funding to start its global pivotal Phase 3 program in 2026.
The FDA’s IND clinical hold on GH001 remains only partly resolved as of July 23, 2025, with a remaining rat respiratory tract histology issue that could delay the start of pivotal U.S. trials.
GH Research posted net losses of $10.8 million in Q1 2025 and $9.3 million in Q2 2025 with no product revenue, pointing to ongoing cash burn risk if development timelines extend.
There is a significant pipeline concentration risk, as the company depends mainly on GH001, with the earlier-stage GH002 only planning its IND for Q4 2025 and GH003 still preclinical, limiting diversification if setbacks arise.
Data summarised monthly by Lightyear AI. Last updated on 30 Sept 2025.
GH Research Financial Performance
Revenues and expenses
GH Research Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for GH Research stock?
GH Research (GHRS) has a market cap of $781M as of October 12, 2025.
What is the P/E ratio for GH Research stock?
The price to earnings (P/E) ratio for GH Research (GHRS) stock is 0 as of October 12, 2025.
Does GH Research stock pay dividends?
No, GH Research (GHRS) stock does not pay dividends to its shareholders as of October 12, 2025.
When is the next GH Research dividend payment date?
GH Research (GHRS) stock does not pay dividends to its shareholders.
What is the beta indicator for GH Research?
GH Research (GHRS) has a beta rating of 0.97. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.